Navigation Links
Epidurals Associated With Breastfeeding Problems

A study done by researchers from University of Sydney suggested that having an epidural to relieve labour pains is associated with problems in breastfeeding//. The study results were published in the December 11 issue of International Breastfeeding Journal.

Researchers, who studied 1,300 women who gave birth between March & October 1997, found that those who have the anaesthetic are more likely to have problems in the first week after birth and to stop breastfeeding early. Moreover they said that the chemical used in epidurals could affect babies.

The researchers who looked at the women's childbirth and breastfeeding history found that out of the 416 who had an epidural, 172 also had a Caesarean section. Around 93 percent of the women in the study breast-fed their baby in the first week after birth, but women who had an epidural were significantly more likely to have difficulties in breast-feeding during the first few days after delivery and to breast-feed less often compared to other women who did not have any pain relief.

The findings of the study contribute to the evidence of the fact that the fentanyl component of epidurals is associated with breast-feeding difficulties – said the authors of the study.

The most likely cause of the problems was due to the presence of fentanyl, an opioid drug widely used as a component of epidurals, capable of passing quickly into the bloodstream and easily cross the placenta to reach the unborn baby. Some of the adverse side effects of the drugs are lowered blood pressure, a slowing of the birth process and a greater risk of having to pull the baby out with forceps.

In a commentary on the research, published today, experts suggested that the impact of epidurals on breast-feeding should be officially classed as an “adverse drug reaction”.
SI
'"/>




Page: 1

Related medicine news :

1. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. Associated therapy for multiple myeloma
4. Associated scan for detecting ovarian cancer spread
5. Ginseng Associated with Pregnancy Risks
6. Enzyme Associated with Memory
7. 3 die, 500 sickened in nations largest hepatitis A outbreak Associated Press
8. Enzyme Associated With Memory
9. Problems Associated With Iron Deficiency
10. Asbestos Exposure Associated With An Increased Risk For Autoimmune Disease
11. Young Patients On Antidepressants Found To Be Associated With Suicidal Tendencies
Post Your Comments:
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Warner Chilcott Announces Secondary Equity Offering 6242 1Warner Chilcott Announces Secondary Equity Offering 6242 2Warner Chilcott Announces Secondary Equity Offering 6242 3Warner Chilcott Announces Secondary Equity Offering 6242 4Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 1Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 2Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 3Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months 6240 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 1Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 2Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 3Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 4Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 5Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 6Kun Run Biotechnology Inc Announces Third Quarter 2009 Results 6238 7
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3